Breast cancer remains one of the most challenging diseases to treat, especially for aggressive forms such as triple-negative breast cancer. Researchers are working relentlessly to better understand tumor metabolism and to find new therapeutic strategies. Two recent studies highlight how critical glutamine metabolism is in breast cancer cells:
Breaking tumors open with Precellys
To understand how tumors survive and resist therapies, scientists first need reliable samples. Precellys allows them to homogenize tumor tissue efficiently, releasing all the molecular information hidden inside. This is the first step to uncovering cancer’s weak spots.
From resistance to vulnerability
Recent studies show how tumors not only depend on glutamine but also use it to resist chemotherapy. By targeting this mechanism, scientists managed to sensitize resistant triple-negative breast cancer cells. Precellys was a key partner in preparing the samples that revealed this breakthrough.
Both breakthroughs relied on Precellys technology to homogenize tumor tissues and extract reliable metabolic data. For scientists, the challenge is clear: how to obtain consistent, reproducible results from difficult samples. Precellys provides the efficiency, speed, and reproducibility required to accelerate discovery.
This Breast Cancer Awareness Month, Bertin Technologies is proud to support cancer research by equipping laboratories worldwide with innovative solutions that help fight breast cancer.
